|drug868||Computer task questionnaires Wiki||1.00|
|drug888||Control for aerosol generating procedures Wiki||1.00|
There is one clinical trial.
The primary goal of this study is to assess use of a biocontainment device for planned airway procedures under general anesthesia. This will serve as a platform for using this device as a novel biocontainment and aerosol evacuation system as part of rapid sequence intubation protocols for COVID-19 patients. We hypothesize that airway procedures with the aerosol biocontainment device will be safe and effective with airway procedure times approaching times for airway procedures without the device.
Description: Assess changes in airway procedure times with and without the biocontainment device as a function of repeated utilization and as a function of patient-associated airway factors (Mallampati score, hyomental distance, neck mobility, BMI) and user-associated airway factors (experience of user, airway device used, induction sequence).Measure: Measuring the time for performing an airway procedure with the biocontainment device when accounting for patient and user-specific factors. Sub-analysis, based on user experience level. Time: Start of airway procedure through to completion of airway procedure.
Description: Assess the perceived ability to learn to use the device with audiovisual and written training methods.Measure: Median values of Likert scale ratings of the post-training questionnaire results to assess perceived device training. Time: through study completion, an average of 2 months
Description: Assess adverse events, adverse device events associated with using the biocontainment device.Measure: Quantifying the number of AEs or ADEs over time to assess device safety. Breakdown of AEs/ADEs as a function of time and by user subject. Time: through study completion, an average of 2 months
Description: Assess the user subject's comfort with using the biocontainment device.Measure: Median Likert ratings from device use survey questions that assess user subject device comfort. Time: At time of consent through 1 week after completion of airway procedure
Description: Assess for additional healthcare and cognitive burden imposed by the device.Measure: Median Likert ratings from device use survey questions that assess user subject healthcare burden with the device. Time: At time of consent through 1 week after completion of airway procedure
Description: Survey of patient's post-procedure on experience being inside the device.Measure: Median Likert rating of the patient questionnaire results to assess patient experience in the device. Time: At time of consent through 1 week after completion of airway procedure
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports